# US 2022/0031849 A1 · Nanoparticle encapsulation to target g protein-coupled receptors in endosomes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031849 A1
- Document ID: US20220031849A1
- Status: Published application
- Kind: A1
- Application number: 17/287,949
- Filed: 2019-10-22
- Published: 2022-02-03
- Earliest claimed: 2018-10-22
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Nigel Bunnett; Thomas Davis; Michael Whittaker; Nicholas Veldhuis
- Web page: https://patentgrep.com/patent/US20220031849A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C08F 220/34: Esters containing nitrogen {, e.g. N,N-dimethylaminoethyl (meth)acrylate}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS

## Abstract

The present invention relates to methods for modulating endosomal GPCR signaling. In particular, the present invention relates to use of polymeric nanoparticles for the targeted delivery of hydrophobic modulators of endosomal GPCRs and their use in the treatment of associated diseases and disorder.

## Claims

### Claim 1

An aqueous liquid comprising polymeric nanoparticles of copolymer chains assembled to form a core/shell structure, the copolymer chains having:
(i) an acid-responsive hydrophobic polymer block that forms the core of the nanoparticles; and
(ii) a hydrophilic polymer block that forms the shell of the nanoparticles and is solvated by the aqueous liquid,
wherein the nanoparticles contain within their core a hydrophobic modulator of endosomal GPCR signaling, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The aqueous liquid according to claim 1, wherein the acid-responsive hydrophobic polymer block comprises tertiary amine functional groups that are protonated in an acidic environment, optionally wherein the tertiary amine functional groups are protonated at about pH=6.1.

### Claim 3 (depends on 1)

The aqueous liquid according to claim 1, wherein the acid-responsive hydrophobic polymer block comprises a homopolymer or copolymer of 2-(diisopropylamino)ethyl methacrylate (DiPAEMA).

### Claim 4 (depends on 1)

The aqueous liquid according to claim 1, wherein the acid-responsive hydrophobic polymer block comprises a copolymer of 2-(diisopropylamino)ethyl methacrylate (DiPAEMA) and a polyalkyleneoxide methacrylate.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The aqueous liquid according to claim 1, wherein the hydrophilic polymer block comprises a copolymer of poly(ethylene glycol)methacrylate (PEGMA) and 2-(dimethylamino)ethyl methacrylate (DMAEMA).

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The aqueous liquid according to claim 1, wherein the hydrophobic modulator of endosomal GPCR signaling or pharmaceutically acceptable salt thereof is an inhibitor of an endosomal GPCR.

### Claim 9 (depends on 1)

The aqueous liquid according to claim 1, wherein the hydrophobic modulator of endosomal GPCR signaling or pharmaceutically acceptable salt thereof is an inhibitor of endosomal NK1R signaling, or pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The aqueous liquid according to claim 1, wherein the hydrophobic modulator of endosomal GPCR signaling or pharmaceutically acceptable salt thereof is selected from the group consisting of aprepitant, fosaprepitant, tradipitant, maropitant, HTX-019, netupitant, serlopitant, orvepitant, NAS-911B, ZD-6021, KD-018, DNK-333, NT-432, NK-949, NT-814, EU-C-001, vestipitant, 1144814, SCH-900978, AZD-2738, BL-1833, casopitant, AV-810, KRP-103, 424887, cizolirtine, vofopitant, L-742694, capsazepine, GR-82334, MEN-11149, L-732138, NiK-004, TA-5538, CP-96345, lanepitant, LY-2590443, dapitant, burapitant, befetupitant, CJ-17493, AVE-5883, CGP-49823, CP-122721, CP-99994, SLV-317, TAK-637, L-733060, L-703606, dilopetine, MPC-4505, L-742311, FK-888, WIN-64821, NIP-530, SLV-336, ezlopitant, TKA-457, figopitant, ZD-4794, CP-100263, GR-203040, L-709210, MEN-10930, MEN-11467, LY-306740, FK-355, WIN-67689, WIN-51708, FK-224, BL-1832, CAM-6108, CP-98984, WS-9326A, L-741671, L-737488, L-740141, L-760735, L-161664, YM-49244, Sch-60059, SDZ-NKT-343, S-18523, RPR-111905, S-19752, L-161644, LY-297911, RPR-107880, L-736281, anthrotainin, RP-73467, WIN-64745, WIN-68577, WIN-62577 WIN-66306, RP-67580, CP-0364, L-743986, S-16474, CGP-47899, FR-113680, YM-44778, GR-138676, CGP-73400, CAM-2445, MDL-105172A, L-756867, isbufylline, R-673, SR-48968 and SR-14033, GW679769, CP-0578, and a pharmaceutically acceptable salt thereof.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The aqueous liquid according to claim 1, wherein the hydrophobic modulator of endosomal GPCR signaling or pharmaceutically acceptable salt thereof is an inhibitor of endosomal CGRP and/or CLR signalling or pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The aqueous liquid according to claim 1, wherein the hydrophobic modulator of endosomal GPCR signaling or pharmaceutically acceptable salt thereof is selected from the group consisting of BI 44370, MK-3207, olcegepant, ubrogepant, rimegepant, SB-268262, telcagepant, and a pharmaceutically acceptable salt thereof.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The aqueous liquid according to claim 1, further comprising a second hydrophobic modulator of endosomal GPCR signaling or a pharmaceutically acceptable salt thereof, wherein the second hydrophobic modulator of endosomal GPCR signalling or pharmaceutically acceptable salt thereof is contained within the core of the polymeric nanoparticles.

### Claim at position 16

16-22. (canceled)

### Claim 23

An aqueous liquid comprising polymeric nanoparticles of copolymer chains assembled to form a core/shell structure, the copolymer chains having:
(i) an acid-responsive hydrophobic polymer block that forms the core of the nanoparticles; and
(ii) a hydrophilic polymer block that forms the shell of the nanoparticles and is solvated by the aqueous liquid,
wherein the nanoparticles contain within their core:
a) a first hydrophobic modulator of endosomal GPCR signaling, or a pharmaceutically acceptable salt thereof, and
b) a second hydrophobic modulator of endosomal GPCR signaling, or a pharmaceutically acceptable salt thereof.

### Claim at position 18

24-38. (canceled)

### Claim 39 (depends on 1)

A pharmaceutical composition comprising the aqueous liquid according to claim 1 and a pharmaceutically acceptable excipient.

### Claim 40 (depends on 1)

A method of modulating endosomal GPCR signaling in a subject in need thereof comprising administering to the subject an effective amount of the aqueous liquid according to claim 1.

### Claim 41 (depends on 40)

The method of claim 40, further comprising administering to the subject an effective amount of a second modulator of endosomal GPCR signaling or a pharmaceutically acceptable salt thereof.

### Claim at position 22

42-49. (canceled)

### Claim 50 (depends on 1)

A method for the treatment of a disease or disorder mediated by endosomal NK1R signaling comprising administering to a subject in need thereof an effective amount of the aqueous liquid according to claim 1.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the disease or disorder mediated by endosomal NK1R signaling is selected from chemotherapy-induced nausea and vomiting (CINV), cyclic vomiting syndrome, postoperative nausea and vomiting, affective and addictive disorders including depression and anxiety, generalised anxiety disorder (GAD), gastrointestinal disorders including inflammatory bowel disease, irritable bowel syndrome, gastroparesis and functional dyspepsia, chronic inflammatory disorders including arthritis, respiratory disorders including COPD and asthma, urogenital disorders, sensory disorders and pain including somatic pain and visceral pain, pruritus, viral and bacterial infections and proliferative disorders (cancer), and combinations thereof.

### Claim at position 25

52-53. (canceled)

### Claim 54 (depends on 50)

The method according to claim 50, further comprising administering to the subject an effective amount of a second modulator of endosomal GPCR signaling or a pharmaceutically acceptable salt thereof.

### Claim at position 27

55-56. (canceled)

### Claim 57 (depends on 1)

A method for the treatment of a disease or disorder mediated by endosomal CGRP and/or CLR signaling comprising administering to a subject in need thereof an effective amount of the aqueous liquid according to claim 1.

### Claim 58 (depends on 57)

The method according to claim 57, wherein the disease or disorder mediated by endosomal CGRP receptor, e.g., CLR signaling is selected from the group consisting of: migraine and symptoms associated with migraine including pain, photophobia, phonophobia, nausea and vomiting, sensory disorders, pain including somatic pain and visceral pain, pain associated with cluster and chronic daily headache, respiratory disorders including COPD and asthma, gastrointestinal disorders including inflammatory bowel disease, irritable bowel syndrome, gastroparesis and functional dyspepsia, and chronic inflammatory disorders including osteoarthritis and rheumatoid arthritis.

### Claim at position 30

59-74. (canceled)
